Human Liver Models Market - Growing Healthcare Market in the Asia Pacific and Latin America

Objectives of this Study:

# To define, measure, and describe the global human liver model market by type and region.

# To provide detailed information about the major factors influencing market growth (drivers, restraints, challenges, and opportunities).

# To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market.

# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.

# To forecast the size of market segments in North America, Europe, Asia Pacific, and RoW

The global human liver models market is expected to reach USD 2.56 Billion by 2022 from USD 1.35 Billion in 2017, at a CAGR of 13.6% during the forecast period (2017-2022).

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171046468

The key factors driving the growth of this market include growing focus on developing alternatives for animal testing models, significant increase in research funding and venture capital investments for the development of liver models, growing initiatives to increase awareness about liver organoids, increasing research activities on liver organoids, increasing prevalence of non-alcoholic fatty liver disease, and growing need for the early detection of drug toxicity to minimize financial losses due to late-stage drug failure.

Target Audience:

# Pharmaceutical and biotechnology companies

# Chemical companies

# Cosmetic product manufacturers, suppliers, and distributors

# Healthcare providers and diagnostic laboratories

# Manufacturers of 3D Cell Culture products

# Food & beverage manufacturers

# Contract research organizations (CROs)

# Research institutes/universities

# Research and consulting firms

# Venture capitalists

North America held the largest share of the market in 2017

In 2017, North America accounted for the largest share of the human liver models market, followed by Europe.

The market for human liver models in this region is driven by the presence of a well-established life sciences industry, growing awareness about the organoids technology, favorable government initiatives, growing incidence of NAFLD, and unavailability of livers for transplantation, increased research spending, rising focus on tissue culture-based clinical diagnostics, and the availability of skilled professionals.

The human liver models market is emerging and fragmented in nature with various regional and international players. In 2016, the liver-on-a-chip and liver 3D bioprinting market was dominated by CN Bio (UK) and Organovo Holdings, Inc. (US), respectively.

The key players in the global human liver models market are Emulate (US), Ascendance Bio (US), HìREL (US), CN Bio (UK), Organovo (US), and Cyfuse Biomedical (Japan).

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=171046468

Human Liver Models Market worth 2.56 Billion USD by 2022

The report “Human Liver Models Market by Drug Discovery Platform (Non-alcoholic Fatty Liver Organoids, Liver-on-a-chip, 2D Models, Animal Models, 3D Bioprinting), and Region (North America, Europe, Asia Pacific, Rest of the World) - Global Forecast to 2022", The global human liver models market is expected to reach USD 2.56 Billion by 2022 from USD 1.35 Billion in 2017, at a CAGR of 13.6% during the forecast period (2017-2022).

The key factors driving the growth of this market include growing focus on developing alternatives for animal testing models, significant increase in research funding and venture capital investments for the development of liver models, growing initiatives to increase awareness about liver organoids, increasing research activities on liver organoids, increasing prevalence of non-alcoholic fatty liver disease, and growing need for the early detection of drug toxicity to minimize financial losses due to late-stage drug failure.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171046468

Objectives of the Study

# To define, measure, and describe the global human liver model market by type and region

# To provide detailed information about the major factors influencing market growth (drivers, restraints, challenges, and opportunities)

# To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market

# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players

# To forecast the size of market segments in North America, Europe, Asia Pacific, and RoW

Animal models accounted for the largest share of the market in 2017

The human liver models market is segmented on the basis of type into liver organoids, liver-on-a-chip, 2D models, animal models, and 3D bioprinting. In 2017, the animal models segment accounted for the largest share of the global market. The growth in the biosimilars market is expected to boost the preclinical market as the development of biosimilars and biopharmaceuticals requires an understanding of the mechanism of action, quantification of pharmacological effects, and interpretation of toxicological data.

Preclinical research also helps in securing a clear definition of targets. Moreover, as the patents for many blockbuster drugs are set to expire by 2020, the demand for biosimilars and preclinical services is likely to increase. The rising demand for preclinical services, in turn is expected to drive the demand for animal models.

Target Audience:

# Pharmaceutical and biotechnology companies

# Chemical companies

# Cosmetic product manufacturers, suppliers, and distributors

# Healthcare providers and diagnostic laboratories

# Manufacturers of 3D Cell Culture products

# Food & beverage manufacturers

# Contract research organizations (CROs)

# Research institutes/universities

# Research and consulting firms

# Venture capitalists

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=171046468

North America held the largest share of the market in 2017

In 2017, North America accounted for the largest share of the human liver models market, followed by Europe.

The market for human liver models in this region is driven by the presence of a well-established life sciences industry, growing awareness about the organoids technology, favorable government initiatives, growing incidence of NAFLD, and unavailability of livers for transplantation, increased research spending, rising focus on tissue culture-based clinical diagnostics, and the availability of skilled professionals.

The key players in the global human liver models market are Emulate (US), Ascendance Bio (US), HìREL (US), CN Bio (UK), Organovo (US), and Cyfuse Biomedical (Japan).

Human Liver Models Market - Emerging Industry Dynamics

Objectives of the Study

# To define, measure, and describe the global human liver model market by type and region

# To provide detailed information about the major factors influencing market growth (drivers, restraints, challenges, and opportunities)

# To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market

# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players

# To forecast the size of market segments in North America, Europe, Asia Pacific, and RoW

Please Share your Specific Interest So That We Can Serve You Better | Download PDF Brochure@ 

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171046468

Factors Influencing Global Growth:-

The key factors driving the growth of this market include growing focus on developing alternatives for animal testing models, significant increase in research funding and venture capital investments for the development of liver models, growing initiatives to increase awareness about liver organoids, increasing research activities on liver organoids, increasing prevalence of non-alcoholic fatty liver disease, and growing need for the early detection of drug toxicity to minimize financial losses due to late-stage drug failure. 

Restraints:

# Issues Related to the Incorporation of Organoids Into Existing Workflows

Opportunities:

# Increasing Focus on Drug Discovery Activities

# Rising Demand for Liver Transplantation

# Growing Healthcare Market in the Asia Pacific and Latin America

Monetary Growth Expectations, Globally:

According to the Research Study conducted by MarketsandMarkets™: The global human liver models market is expected to reach USD 2.56 Billion by 2022 from USD 1.35 Billion in 2017, at a CAGR of 13.6% during the forecast period (2017-2022).

Please Share your Specific Interest So That We Can Serve You Better | Request Sample Pages@ 

https://www.marketsandmarkets.com/requestsampleNew.asp?id=171046468

Geographical Growth Scenario:

Geographic segments in this report include North America, Europe, Asia Pacific, and the RoW. Of these, the North American segment accounted for the largest share of the market in 2017. The human liver market for North America is driven by the presence of a well-established life sciences industry, growing awareness about the organoids technology, increasing government funding, growing incidence of NAFLD, and unavailability of livers for transplantation, increasing investments on research, rising focus on tissue culture-based clinical diagnostics, and the availability of skilled professionals.

Leading Market Players:

# Emulate (US)

# Ascendance Bio (US)

# HìREL (US)

# CN Bio (UK)

# Organovo (US)

# Cyfuse Biomedical (Japan) and many more…

Human Liver Models Industry - Major Factors Boosting the Future | Emerging Trends

Objectives of this Study:-

# To define, measure, and describe the global human liver model market by type and region

# To provide detailed information about the major factors influencing market growth (drivers, restraints, challenges, and opportunities)

# To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market

# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players

# To forecast the size of market segments in North America, Europe, Asia Pacific, and RoW

Global Market Dynamics:

Major Industry Growth Drivers:

# Growing Focus on Developing Alternatives for Animal Testing Models

# Significant Increase in Research Funding and Venture Capital Investments for the Development of Liver Organoids

# Growing Initiatives to Increase Awareness about Liver Organoids

# Increasing Research Activities on Liver Organoids

# Increasing Prevalence of Non-Alcoholic Fatty Liver Disease

# Growing Need for the Early Detection of Drug Toxicity to Minimize Financial Losses Due to Late-Stage Drug Failure

Looking Out for More Details | Download the PDF Brochure@ 

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=171046468

Major Growth Restraints:

# Issues Related to the Incorporation of Organoids into Existing Workflows

Opportunities:

# Increasing Focus on Drug Discovery Activities

# Rising Demand for Liver Transplantation

# Growing Healthcare Market in the Asia Pacific and Latin America

Industry’s Revenue Growth Expectations:

The global human liver models market is expected to reach USD 2.56 Billion by 2022 from USD 1.35 Billion in 2017, at a CAGR of 13.6% during the forecast period (2017-2022).

Geographical Growth Scenario:

Geographic segments in this report include North America, Europe, Asia Pacific, and the RoW. Of these, the North American segment accounted for the largest share of the market in 2017. The human liver market for North America is driven by the presence of a well-established life sciences industry, growing awareness about the organoids technology, increasing government funding, growing incidence of NAFLD, and unavailability of livers for transplantation, increasing investments on research, rising focus on tissue culture-based clinical diagnostics, and the availability of skilled professionals.

Read More: https://www.marketsandmarkets.com/PressReleases/human-liver-model.asp

Leading Market Players:

The major players in the global human liver model market are Emulate (US), Ascendance Bio (US), HìREL (US), CN Bio (UK), Organovo (US), and Cyfuse Biomedical (Japan).

The global liver 3D bioprinting market was dominated by Organovo Holdings, Inc. (US). With its broad product portfolio, Organovo Holdings, Inc. held the leadership position in the global 3D bioprinting market for liver in 2016. Its large market share is attributed to its robust 3D bioprinting portfolio. In addition, the company is focusing on various strategies to expand its product offerings and increase its visibility in the 3D bioprinting market.

In line with this, the company has collaborated with various research organizations and pharmaceutical companies for developing novel products. For instance, in June 2016, Organovo collaborated with the University of California, San Francisco (UCSF) for developing 3D bioprinted tissues, to be used for research on skeletal disease. Similarly, in December 2014, Organovo collaborated with the Yale School of Medicine, Department of Surgery (US) with the aim to develop 3D organ tissues for surgical transplantation research.

Target Audience:

# Pharmaceutical and biotechnology companies

# Chemical companies

# Cosmetic product manufacturers, suppliers, and distributors

# Healthcare providers and diagnostic laboratories

# Manufacturers of 3D Cell Culture products

# Food & beverage manufacturers

# Contract research organizations (CROs)

# Research institutes/universities

# Research and consulting firms

# Venture capitalists

Human Liver Models Market - Global Market Leaders

Browse 7 market data Tables and 2 Figures spread through 37 Pages and in-depth TOC on "Human Liver Models Market"

https://www.marketsandmarkets.com/Market-Reports/human-liver-model-market-171046468.html

Early buyers will receive 10% customization on reports.

[37 Pages Report] The global human liver models market was valued at USD 1.23 Billion in 2016 and is projected to reach USD 2.56 Billion by 2022, at a CAGR of 13.6% during the forecast period. Base year considered for the report is 2016 and the forecast period considered for this report is 2017–2022.

Objectives of the Study:

• To define, measure, and describe the global human liver model market by type and region
• To provide detailed information about the major factors influencing market growth (drivers, restraints, challenges, and opportunities)
• To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
• To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
• To forecast the size of market segments in North America, Europe, Asia Pacific, and RoW

Download the PDF Brochure for More Details@ http://bit.ly/2SAS340

CN Bio held the leading position in the global liver-on-a-chip market in 2016. The company offers its products and services for drug discovery and drug safety programs. To enhance its production capabilities and applications, the company focuses on adopting inorganic strategies such as collaborations and agreements.

Over the last three years, CN Bio has been a part of six such initiatives that helped the company enhance its presence in this market. For instance, in 2017, CN Bio collaborated with AstraZeneca (UK) to validate a new in vitro tool to predict optimized drug dosing regimens for multi-drug therapies. Furthermore, in 2015, CN Bio collaborated with Alnylam Pharmaceuticals (US) to test and develop therapeutics for liver diseases and infections by using LiverChip, CN Bio’s human liver-on-a-chip platform.

The global liver 3D bioprinting market was dominated by Organovo Holdings, Inc. (US). With its broad product portfolio, Organovo Holdings, Inc. held the leadership position in the global 3D bioprinting market for liver in 2016. Its large market share is attributed to its robust 3D bioprinting portfolio. In addition, the company is focusing on various strategies to expand its product offerings and increase its visibility in the 3D bioprinting market. 

In line with this, the company has collaborated with various research organizations and pharmaceutical companies for developing novel products. For instance, in June 2016, Organovo collaborated with the University of California, San Francisco (UCSF) for developing 3D bioprinted tissues, to be used for research on skeletal disease. Similarly, in December 2014, Organovo collaborated with the Yale School of Medicine, Department of Surgery (US) with the aim to develop 3D organ tissues for surgical transplantation research.

You Can Also Get In-Touch with Our Research Experts for More Detailed Information

Target Audience:

• Pharmaceutical and biotechnology companies
• Chemical companies
• Cosmetic product manufacturers, suppliers, and distributors
• Healthcare providers and diagnostic laboratories
• Manufacturers of 3D cell culture products
• Food & beverage manufacturers
• Contract research organizations (CROs)
• Research institutes/universities
• Research and consulting firms
• Venture capitalists

Scope of the Report:

The research report categorizes the human liver model market into the following segments and subsegments:

Human Liver Model Market, by Type

• Liver Organoids
• Liver-on-a-chip
• 2D Models
• Animal Models
• 3D Bioprinting

Human Liver Model Market, by Region

• North America
• Europe
• Asia Pacific
• Rest of the World